Sicriptin 2.5 mg Tablets (Bromocriptine)

Sicriptin 2.5 mg Tablets, manufactured by Serum Institute India, are a prescription medication formulated to address conditions linked to elevated prolactin levels. Each strip contains ten film‑coated tablets, and the product is available in pack sizes of 30, 60, or 90 tablets to suit extended treatment regimens. The medication is classified under Diabetes Care, reflecting its dual role in managing metabolic disturbances and supporting reproductive health in women.

The active ingredient, bromocriptine, is a synthetic ergot alkaloid that functions as a dopamine D2 receptor agonist. By stimulating dopamine receptors in the hypothalamus, Sicriptin reduces the secretion of prolactin from the anterior pituitary gland. This physiological action helps restore regular menstrual cycles, improves ovulation rates, and may also contribute to better glycemic control in select patients with type 2 diabetes mellitus. (Learn more on Wikipedia.)

What is Sicriptin 2.5 mg Tablets (Bromocriptine)

Sicriptin is the brand name for bromocriptine mesylate, a synthetic ergot alkaloid that functions as a dopamine D2 receptor agonist. By stimulating dopamine receptors in the hypothalamus, Sicriptin reduces the secretion of prolactin from the anterior pituitary gland. This physiological action helps restore regular menstrual cycles, improves ovulation rates, and may also contribute to better glycemic control in select patients with type 2 diabetes mellitus. (Learn more on Wikipedia.)

Clinically, physicians prescribe Sicriptin to women experiencing ovulatory dysfunction due to elevated prolactin, as well as to patients with type 2 diabetes who have associated hormonal disturbances. The standard starting dose is 2.5 mg taken once daily, with titration possible based on clinical response and serum prolactin levels.

Uses and Benefits

In the realm of reproductive medicine, Sicriptin assists women with pituitary‑derived infertility by normalizing prolactin, thereby restoring the delicate feedback loop that regulates ovarian function.

Beyond fertility, the drug offers metabolic benefits for individuals with type 2 diabetes who also exhibit elevated prolactin. By improving insulin sensitivity and modestly lowering fasting glucose, bromocriptine can complement conventional antidiabetic agents, especially when patients struggle with weight management or have comorbid hormonal disturbances.

The benefits of Sicriptin extend to its well‑characterized safety profile when used as directed. Compared with alternative dopamine agonists, bromocriptine presents a lower incidence of certain cardiovascular side effects, making it a suitable option for patients with a history of hypertension or cardiac disease, provided they are monitored regularly.

How It Works

Bromocriptine exerts its pharmacological effect by binding to D2 receptors on lactotroph cells in the anterior pituitary. This binding triggers a cascade that inhibits the release of prolactin, leading to a rapid decline in circulating hormone levels.

The reduction in prolactin can reverse the suppression of gonadotropin‑releasing hormone (GnRH), which in turn stimulates the secretion of luteinizing hormone (LH) and follicle‑stimulating hormone (FSH), essential for follicular development and ovulation.

Pharmacodynamically, the drug reaches peak plasma concentrations within one to two hours after oral administration, with a half‑life of approximately 12 hours. This pharmacokinetic profile supports once‑or twice‑daily dosing regimens, allowing clinicians to tailor treatment plans to patient convenience and lifestyle. (Refer to the NIH’s overview of dopaminergic agents NIH for detailed pharmacokinetics.)

Dosage Guidelines

For the treatment of female infertility associated with hyperprolactinemia, the usual starting dose is 2.5 mg taken once daily, preferably with food to minimize gastrointestinal discomfort.

Dosage may be titrated upward in 2.5 mg increments at intervals of one to two weeks, based on serum prolactin levels and clinical response, up to a maximum of 10 mg per day if needed.

In patients with type 2 diabetes, the initial recommendation mirrors the infertility protocol, but many clinicians maintain the dose at 2.5 mg daily for a minimum of eight weeks before assessing glycemic parameters. Adjustments should be made cautiously, especially in individuals with renal impairment, as the drug is primarily metabolized hepatic and excreted renally. (See FDA safety guidance FDA for monitoring recommendations.)

Side Effects

Most individuals tolerate bromocriptine well, but like all medications, it can produce adverse effects. The most frequently reported side effects include nausea, vomiting, dizziness, and headache, which are usually mild and transient.

Less common but clinically significant reactions may involve orthostatic hypotension, valvular heart disease, and psychiatric symptoms such as depression or anxiety.

Rarely, patients may experience fibrotic changes in cardiac valves, a concern highlighted by FDA safety communications. (FDA)

Warnings and Precautions

Sicriptin is contraindicated in patients with known hypersensitivity to bromocriptine or any component of the formulation. It should not be used during pregnancy unless the potential benefit outweighs the risk, and breastfeeding is discouraged due to the possibility of drug transfer into milk.

Concurrent use of other ergot alkaloids or dopamine antagonists may diminish efficacy or increase the likelihood of side effects, so a thorough medication reconciliation is essential. Additionally, caution is advised in patients with uncontrolled hypertension, as bromocriptine can cause abrupt drops in blood pressure, particularly after the first dose. (FDA safety guidance)

Healthcare providers should counsel patients to undergo regular laboratory monitoring, including prolactin levels and liver function tests, to gauge treatment response and detect any emerging safety signals. Education about lifestyle modifications—such as balanced nutrition and regular physical activity—can enhance overall outcomes, especially in the management of diabetes.

Frequently Asked Questions

What conditions does Sicriptin 2.5 mg Tablet treat?

Sicriptin is indicated for female infertility caused by elevated prolactin, increased prolactin levels due to pituitary disorders, and as an adjunct in the management of type 2 diabetes when hormonal factors affect glycemic control.

How should I take Sicriptin?

Take one tablet orally once daily with food and a full glass of water. Do not crush or chew the tablet. Dosage may be adjusted by your physician based on response and blood test results.

What are the most common side effects?

Common side effects include nausea, headache, dizziness, and mild abdominal discomfort. If these symptoms persist or become severe, contact your healthcare provider.

Can I use Sicriptin if I am pregnant or breastfeeding?

Sicriptin is not recommended during pregnancy unless specifically prescribed by a physician, and it should be avoided while breastfeeding, as the drug may pass into milk and affect the infant.

Where can I find more detailed information?

For comprehensive prescribing details, refer to the FDA label (FDA), MedlinePlus entry for bromocriptine (MedlinePlus), or the NIH’s clinical resources (NIH). You may also review the product monograph on Drugs.com (Drugs.com) for patient‑focused guidance.

Related Products

• CB-Lin (Cabergoline)
• Meprate 10 mg (Medroxyprogesterone)
• Sicriptin 1.25 mg Tablets (Bromocriptine)
• Sicriptin (Bromocriptine)
• Bromocriptine 1.25 mg (Generic)
• Bromocriptine 2.5 mg (Generic)
• Sifasi Aqua 5000 (HCG (Human Chorionic Gonadotropin))
• Clomiphene 25 mg (Generic)
• Siphene 100 mg (Clomiphene)
• Siphene 50 mg (Clomiphene)
• Siphene M 25 mg (Clomiphene)
• Siphene (Clomiphene)